Перелік літератури для №8-2018 «З турботою про Жінку»

«Послеродовое кровотечение и хирургические подходы, позволяющие сохранить матку»

Uzel Kemine, Ahmet Kale, Gulfem Basol, Chora Aifer

  1. WHO. Reducing the Global Burden: Postpartum Haemorrhage. Making Pregnancy Safer. 2007. [Full Text].

       2.American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum                      hemorrhage. Obstet Gynecol. 2006 Oct. 108(4):1039-47. [Medline].

  1. Lutomski J, Byrne B, Devane D, Greene R. Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study. BJOG. 2012 Feb. 119(3):306-14. [Medline].
  2. Baskett TF. Complications of the third stage of labour. Essential Management of Obstetrical Emergencies. 3rd ed. Bristol, England: Clinical Press; 1999. 196-201.
  3. Sentilhes L, Vayssière C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016 Mar. 198:12-21. [Medline].
  4. Jackson KW Jr, Allbert JR, Schemmer GK, Elliot M, Humphrey A, Taylor J. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol. 2001 Oct. 185(4):873-7. [Medline].
  5. Society of Obstetrics and Gynecology of Canada. Postpartum hemorrhage. ALARM Manual. 15th Ed. 2008.

       8.Jaleel R. Khan A. Post-partum haemorrhage--a risk factor analysis. Mymensingh Medical Journal: MMJ. 19(2):282-9, 2010 Apr. Abstract

  1. Rogers MS, Yuen PM, Wong S. Avoiding manual removal of placenta: evaluation of intra-umbilical injection of uterotonics using the Pipingas technique for management of adherent placenta. Acta Obstet Gynecol Scand. 2007. 86(1):48-54. [Medline].

     10.Visually estimated and calculated blood loss in vaginal and cesarean delivery Irene Stafford, MD; Gary A. Dildy; Steven L. Clark; Michael A. Belfort,            http://www.ncbi.nlm.nih.gov/pubmed/18639209

  1. Rogers J, Wood J, McCandlish R, Ayers S, Truesdale A, Elbourne D. Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet. 1998 Mar 7. 351(9104):693-9. [Medline]

     12.[Guideline] James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international                 expert panel. Am J Obstet Gynecol. 2009 Jul. 201(1):12.e1-8. [Medline].

     13.Baskett TF. Complications of the third stage of labour. Essential Management of Obstetrical Emergencies. 3rd ed. Bristol, England: Clinical Press; 1999. 196-201.

     14.O’Leary JA.Uterine artery ligation in the control of postcesarean hemorrhage.JReprod Med 1995;40:189.

  1. Pelvic arterial ligations for severe post-partum hemorrhage. Indications and techniques. Morel O Malartic C Muhlstein J ,Gayat E, Judlin P, Soyer P, Barranger E. J Visc Surg. 2011 Apr;148(2):e95-102. Doi: 10.1016/j.jviscsurg.2011.02.002.Epub 2011 Apr 7.
  2. Tsirulnikov MS. Ligation of the uterine vessels during obstetrical hemorrhages. Immediate and long-term results. J Gynecol Obstet Biol Reprod 1979;8:751-3.
  3. AbdRabbo SA. Stepwise uterine devascularization: a novel technique for management of uncontrolled postpartum hemorrhage with preservation of the uterus. Am J Obstet Gynecol 1994; 171:694.
  4. Sentilhes L, Trichot C Resch B, et al. Fertility and pregnancy outcomes following uterine devascularization for severe postpartum haemorrhage. Hum Reprod 2008;23:1087.
  5. AbdRabbo SA. Stepwise uterine devascularization: a novel technique for management of uncontrolled postpartum hemorrhage with preservation of the uterus. Am J Obstet Gynecol. 1994 Sep. 171(3):694-700. [Medline].
  6. The B-Lynch technique for postpartum haemorrhage: an option for every gynaecologist. Holtsema H, Nijland R, Huisman A, Dony J, van den Berg PP. Eur J Obstet Gynecol Reprod Biol. 2004 Jul 15;115(1):39-42.
  7. Gottlieb G, Pandipati S, Davis KM, Gibbs RS. Uterine necrosis: a complication of uterine compression sutures. Obstet Gynecol 2008;112:429.
  8. Gizzo S, Saccardi C, Patrelli TS, et al. Fertility rate and subsequent pregnancy outcomes after conservative surgical techniques in postpartum hemorrhage: 15 years of literature. Fertil Steril 2013;99:2097
  9. Doumouchtsis SK, Nikolopoulos K, Talaulikar V, et al. Menstrual and fertility outcomes following the surgical management of postpartum haemorrhage: a systematic review. BJOG 2014; 121:382.
  10. Technical description of the B-Lynch brace suture for treatment of massive postpartum hemorrhage and reviev of published cases. Price N, B-Lynch C.

     25.Dildy GA, Belfort MA, Adair CD, et al. Initial experience with a dual-balloon catheter for the management of postpartum hemorrhage. Am J Obstet Gynecol 2014; 210:136.el.

  1. Joshi VM, Otiv SR, Majumder R, et al. Internal iliac artery ligation for attesting postpartum haemorrhage. BJOG 2007;114:356.
  2. Vedantham S, Goodwin SC, McLucas B, Mohr G. Uterine artery embolization: an underused method of controlling pelvic hemorrhage. Am J Obstet Gynecol. 1997 Apr. 176(4):938-48. [Medline].
  3. Pelage JP, Le Dref O, Mateo J, et al. Life-threatening primary postpartum hemorrhage: treatment with emergency selective arterial embolization. Radiology. 1998 Aug. 208(2):359-62. [Medline].
  4. Park HS, Shin JH, Yoon HK, et al. Transcatheter Arterial Embolization for Secondary Postpartum Hemorrhage: Outcome in 52 Patients at a Single Tertiary Referral Center. J Vasc Interv Radiol. 2014 Jun 27. [Medline].

 

«Профілактика артеріальної гіпертензії у жінок із СПКЯ. Міждисциплінарний підхід»

Ігор Лахно

  1. Грищенко О. В., Лахно И. В. Гинекологическая эндокринология: исторический очерк (лекция для будущих акушеров-гинекологов) // Вiсник Харкiвського нацiонального унiверситету iм. В.Н. Каразiна. – 2000. – № 494. Сер.: Медицина. – Вип. 1. – С. 10 – 13.
  2. Лахно И. В. Повышение эффективности методов индукции овуляции у женщин с поликистозом яичников // Здоровье женщины. – 2014. – № 5. – С. 122-125.
  3. Миронова М. П., Фазлыева Э. А. Особенности индукции овуляции у женщин различного возраста с синдромом поликистозных яичников // Акушерство, гинекология и репродукция. – 2013. – № 3 – С. 9-12.
  4. Морчиладзе А. З., Савина В. А., Ткаченко Н. Н., Ярмолинская М. И. Применение ингибитора ароматазы летрозола для индукции овуляции у женщин с синдромом поликистозных яичников // Журнал акушерства и женских болезней. – 2011.– № 2. – С. 52-57.
  5. Рыбалка А.Н., Памфамиров Ю.К., Заболотнов В.А. и др. Индукция овуляции у больных с синдромом поликистозных яичников // Медицинские аспекты здоровья женщины. – 2009. – Т. 25, №8. – С. 12-20.
  6. Azziz R. Introduction: Determinants of polycystic ovary syndrome // Fertil Steril. – 2016. – Vol. 106, No 1. – P. 4-5.
  7. Badawy A., Elnashar A. Treatment options for polycystic ovary syndrome. Review // International Journal of women Health. – 2011. –Vol.3. – P.25-35.
  8. Cahil D. J., O’Brien K. Polycystic ovary syndrome (PCOS): metformin // BMJ Clin Evid. – 2015. – P. 1408.
  9. Costabile L. High dose of phytoestrogens can reverse the antiestrogenic effects of clomiphene citrate on the endometrium in patients undergoing intrauterine insemination: a randomized trial // – 2003. – Vol. 44, Suppl 1. – P. 9-20.
  10. Frossing S., Nylander M., Kistorp C., Skouby S. O., Faber J. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS // Endocr Connect. – 2018. – Vol. 7, No 1. – P. 115-123.
  11. Gerhard I. I., Patek A., Monga B. et al. Mastodynon bei weiblicher Sterilitat // Forsch Komplementarmed. – 1998. – Vol. 5. – P. 272-278.
  12. Glintborg D., Rubin K. H., Nybo M., Abrahamsen B., Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome // Cardiovasc Diabetol. – 2018. – Vol. 17, No 37.
  13. Homburg R., Gudi A., Amit Shah A., Layton A. M. A novel method to demonstrate that pregnant women with polycystic ovary syndrome hyper-expose their fetus to androgens as a possible stepping stone for the developmental theory of PCOS. A pilot study // Reproductive Biology and Endocrinology. – – Vol. 15, No 61. 
  14. Kamel H. H. Role of phyto-oestrogens in ovulation induction in women with polycystic ovarian syndrome // Eur J Obstet Gynecol Reprod Biol. – – Vol. 168, No 1. – P. 60-63.
  15. Kianbakht S., Dabaghian F. H. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial // Complement Ther Med. - 2013. - Vol. 21, No 5. - P. 441-446.
  16. Kim M. W., Ahn K. H., Ryu K. J. et al. Preventive effects offolic Acid supplementation on adverse maternal and fetal outcomes // PLoS One. – 2014. – Vol. 9, No 5. – e 97273. 
  17. Legro R. S., Barnhart H. X., Schlaff W. D. et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome // New England Journal of Medicine. – 2007. – Vol. 356. – P. 551-566.
  18. Marciniak A., Nawrocka Rutkowska J., Brodowska A., Wiśniewska B., Starczewski A. Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention // Ann Agric Environ Med. – 2016. – Vol. 23, No 4. – P. 537-541.
  19. Moll E., Bossuyt P. M., Korevaar J.C. et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial // BMJ. – 2006. –Vol. 332. – P. 1485- 1490.
  20. Patel S. S., Truong U., King M., et al. Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers // Vasc Med . 2017 April ; 22(2): 85–95.
  21. Wiweko B., Indra I., Susanto C., Natadisastra M., Hestiantoro A. The correlation between serum AMH and HOMA-IR among PCOS phenotypes // BMC Res Notes. – 2018. – Vol. 11, No 114.
  22. Wuttke W., Jarry H., Becker T. et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? // Ther Adv Endocrinol Metab. – – Vol.  3, No 1. – P. 27-47.

 

«СTLA-4 та PD-1 – захист ракових клітин від імунної системи заблоковано Нобелівська премія в галузі медицини та фізіології 2018 року»

Ольга Боженко

       1. Cancer Today (powered by GLOBOCAN 2018) IARC; Cancer Base No. 15 Edited by Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray FISBN-13                (Database)

  1. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.
  2. Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in Immunity and Diseases. Curr Top Microbiol Immunol.2017;410:75-97. doi: 10.1007/82_2017_67.
  3. Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9.
  4. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Сancer Res.2011 Jul 15;17(14):4622-8. doi: 10.1158/1078-0432.CCR-10-2232. Epub 2011 Apr 5.
  5. nobelprize.org

 

«Гостра кишкова непрохідність у вагітних»

Євген Гріжимальський, Дмитро Шадлун, Олександр Іоффе, Андрій Гарга, Євгеній Суліменко

  1. Айламазян Э.К., Семенова И.И., Старовойтов В.А. Особенности терапевтической и акушерской тактики при острой кишечной непроходимости у беременных. Вестн. Рос. ассоц. акуш. и гин. 1995; 1 (3): 42–8.
  2. Сотниченко Б.А., Макаров В.И. Ошибки диагностики и хирургической тактики при острой кишечной непроходимости у беременных. Хирургия. 1990; 3: 83–6.
  3. Kehlet H. Fast-track surgery-the role of anaesthesiologist and perioperative pain management. Refresher course lectures. Munich, 2007, pp 153-155

 

«Синдром полікістозних яєчників з точки зору ендокринолога»

Aleksandra Kruszynska

  1. Rotterdam ESHRE/ASRM – sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
  2. Fauser BC, Tarlatzis BC, Rebar RW et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97(1):28-38.
  3. Neil F. Goodman, Rhoda H. Cobin, Walter Futterweit, Jennifer S. Glueck, Richard S. Legro, Enrico Carmina, AACE/ACE Disease State Clinical Review AACE/ACE: Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome-Part 1, ENDOCRINE PRACTICE Vol 21 No. 11 November 2015; 1291.
  4. Neil F. Goodman, Rhoda H. Cobin, Walter Futterweit, Jennifer S. Glueck, Richard S. Legro, Enrico Carmina, AACE/ACE Disease State Clinical Review AACE/ACE: Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome-Part 2, ENDOCRINE PRACTICE Vol 21 No. 12 December 2015; 1415.
  5. Azziz R, Carmina E et al. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab 2006; 91: 4237 – 4245.
  6. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440–1447.
  7. Stein I, Leventhal M. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181–185.
  8. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9: 505–514.
  9. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50: 197–212.
  10. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss 3rd JF, Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 1999; 96: 8573-8578.
  11. Aleksandra Kruszyńska, Jadwiga Słowinska-Srzednicka, Aleksandra Wycisk, Piotr Glinicki, Katarzyna Podkowska, Renata Kapuścińska, High prevalence of autoimmune thyroiditis in Polish PCOS women and its association with insulin resistance Postępy Nauk Medycznych 12/2016, s. 873-877.
  12. Aleksandra Kruszyńska, Jadwiga Słowińska-Srzednicka, Wojciech Jeske, Wojciech Zgliczyński Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS) — the effect of metformin treatment Endokrynologia Polska 2014;65(1):2-10.
  13. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18(6):774-800.
  14. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352(12):1223-1236.
  15. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92(12):4546-4556.
  16. American Diabetes Association 2007 Standards of medical care in diabetes-2007. Diabetes Care 30 (Suppl 1): S4-S41. 2007.
  17. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: number 41, December 2002. Obstet Gynecol 2002; 100(6):1389-1402.
  18. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37(2):119-125.
  19. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92(12):4609-4614.
  20. Shaw LJ, Bairey Merz CN, Azziz R et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93(4):1276-1284.
  21. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003; 14(8):365-370.
  22. Ibáñez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev. 2000;21:671-696.
  23. Janssen OE, Mehlmauer N, Hahn S et al.: High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004; 150(3): 363-369.

 

«Дефіцит вітаміну D у дорослих (частина 2)»

Наталія Товстолиткіна

  1. Bikle D.D. Vitamin D: Newly Discovered Actions Require Reconsideration of Physiologic Requirements [Текст] / D.D. Bikle // Trends Endocrinol. Metab. — 2010. — Vol. 21(6). — P. 375­384.
  2. Дефіцит вітаміну D у населення України та фактори ризику його розвитку Журнал "Біль. Суглоби. Хребет" 4 (08) 2012
  1. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72(3) 690–693.
  2. Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, et al. (2010) Adiposity, cardiometabolic risk, and vitamin D status: The Framingham heart study. Diabetes 59(1) 242–246.
  3. Delvin EE, Lambert M, Levy E, O'Loughlin J, Mark S, et al. (2010) Vitamin D status is modestly associated with glycemia and indicators of lipid metabolism in french-canadian children and adolescents. J Nutr 140 (5) 987–991.
  4. Freedman BI, Wagenknecht LE, Hairston KG, Bowden DW, Carr JJ, et al. (2010) Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab 95 (3) 1076–1083. Підкреслено - ожиріння
  5. Heaney RP, Recker RR, Grote J, Horst RL, Armas LAG (2011) Vitamin D3 is more potent than vitamin D2 in humans. J Clin Endocrinol Metab 96 (3) E447–E452.
  6. Rosenblum JL, Castro VM, Moore CE, Kaplan LM (2012) Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr 95 (1) 101–108.
  7. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78:1463-1470 [PubMed]
  8. Arvold DS, Odean MJ, Dornfeld MP, et al. Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial. Endocr Pract. 2009;15:203-212 [PubMed]
  9. Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest. 1993 Jun. 91(6):2552-5. [Medline]. [Full Text].
  10. Krzyścin JW, Jarosławski J, Sobolewski PS. A mathematical model for seasonal variability of vitamin D due to solar ra diation. J Photochem Photobiol B (2011) 105(1):106–12.10.1016/j.jphotobiol.2011.07.008 [PubMed] [Cross Ref]
  11. Spiro A, Buttriss JL. Vitamin D: an overview of vitamin D status and intake in Europe. Nutr Bull (2014) 39:322–50.10.1111/nbu.12108 [PMC free article] [PubMed] [Cross Ref]
  12. Mayo Clin Proc. 2010 Aug; 85(8): 752–758. Vitamin D Deficiency in Adults: When to Test and How to Treat.
  13. .Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2011) 96(1):53–8.10.1210/jc.2010-2704 [PMC free article] [PubMed] [Cross Ref
  14. Reusch J, Ackermann H, Badenhoop K. Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population. Horm Metab Res. 2009;41:402-407
  15. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 96(7):1911–30.10.1210/jc.2011-0385 [PubMed] [Cross Ref]
  16. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr (2008) 88(2):491S–9S.10.1093/ajcn/88.2.491S [PubMed] [Cross Ref]
  17. Hollis BW, Wagner CL, Drezner MK, Binkley NC. Circulating vitamin D3 and 25-hydroxyvitamin D in humans: an important tool to define adequate nutritional vitamin D status. J Steroid Biochem Mol Biol (2007) 103(3–5):631–4.10.1016/j.jsbmb.2006.12.066 [PMC free article] [PubMed] [Cross Ref
  18. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res (2010) 25(2):305–12.10.1359/jbmr.090728 [PubMed]
  19. Hollis BW, Wagner CL. New insights into the vitamin D requirements during pregnancy. Bone Res (2017) 5:17030.10.1038/boneres.2017.30 [PMC free article] [PubMed] [Cross Ref]
  20. Hollis BW, Wagner CL. Vitamin D supplementation during pregnancy: improvements in birth outcomes and complications through direct genomic alteration. Mol Cell Endocrinol (2017) 453:113–30.10.1016/j.mce.2017.01.039 [PubMed] [Cross Ref]
  21. Wagner CL, Hollis BW, Kotsa K, Fakhoury H, Karras SN. Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. Rev Endocr Metab Disord (2017) 18(3):307–22.10.1007/s11154-017-9414-3 [PubMed] [Cross Ref]
  22. Глобальні рекомендації консенсусу щодо запобігання та менеджменту харчового рахіту The Journal of Clinical Endocrinology & Metabolism, Volume 101, Issue 2, 1 February 2016, Pages 394–415
  23. Vitamin D Supplementation Guidelines for General Population and Groups at Risk of Vitamin D Deficiency in Poland—Recommendations of the Polish Society of Pediatric Endocrinology and Diabetes and the Expert Panel With Participation of National Specialist Consultants and Representatives of Scientific Societies—2018 Update
  24. Pepper KJ, Judd SE, Nanes MS, Tangpricha V. Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. Endocr Pract. 2009;15:95-103
  25. Ginde AA, Scragg R, Schwartz RS, Camargo CA., Jr Prospective study of serum 25-hydroxyvitamin d level, cardiovascular disease mortality, and all-cause mortality in older U.S. Adults. J Am Geriatr Soc. 2009;57:1595-1603
  26. Chandra P, Wolfenden LL, Ziegler TR, et al. Treatment of vitamin D deficiency with UV light in patients with malabsorption syndromes: a case series. Photodermatol Photoimmunol PhotoMed. 2007;23:179-185
  27. WHO • Guideline Vitamin D supplementation in pregnant women, 2012
  28. Hathcock JN et al. Risk assessment for vitamin D. American Journal of Clinical Nutrition 2007, 85:6–18.
  29. Heaney RP. Vitamin D: criteria for safety and efficacy Nutrition Reviews, 2008, 66(Suppl. 2):S178–S181.
  30. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level American Journal of Clinical Nutrition2001, 73:288–294.
  1. Aloia JF et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. American Journal of Clinical Nutrition2008, 87:1952–1958.
  1. Hollis BW et al. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness Journal of Bone and Mineral Research2011, 26:2341–23
  2. Vitamin D Toxicity: A 16-Year Retrospective Study at an Academic Medical Center John P Lee, DO Michael Tansey, MD Jennifer G Jetton, MD Volume 49, Issue 2, 21 March 2018, Pages 123–129, https://doi.org/10.1093/labmed/lmx07713 January 2018
  3. Czech-Kowalska J, Dobrzanska A, Pleskaczynska A, Malinowska E, Gruszfeld D, Karczmarewicz E, et al. Vitamin D status in premature infants at term. Bone (2009) 45(Suppl 2):S107.10.1016/j.bone.2009.04.181
  4. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S-586S [PubMed]
  5. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D. Dosing with ergocalciferol or cholecalciferol, 1,600 IU daily or 50,000 IU monthly, is safe but does not assure vitamin D adequacy. J Bone Miner Res. 2009;24 (suppl 1).
  6. Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract (2013) 28(2):194–208.10.1177/0884533612467824 [PMC free article] [PubMed] [Cross Ref]
  7. Arora E, Singh H, Gupta YK. Impact of antiepileptic drugs on bone health: need for monitoring, treatment, and prevention strategies. J Family Med Prim Care (2016) 5(2):248–53.10.4103/2249-4863.192338 [PMC free article] [PubMed] [Cross Ref]
  8. Fan HC, Lee HS, Chang KP, Lee YY, Lai HC, Hung PL, et al. The impact of anti-epileptic drugs on growth and bone metabolism. Int J Mol Sci (2016) 17(8):E1242.10.3390/ijms17081242 [PMC free article] [PubMed] [Cross Ref]
  9. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387-5391 [PubMed]
  10. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677-681 [PMC free article] [PubMed]
  11. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D. Dosing with ergocalciferol or cholecalciferol, 1,600 IU daily or 50,000 IU monthly, is safe but does not assure vitamin D adequacy. J Bone Miner Res. 2009;24 (suppl 1).
  12. Estimating Vitamin D Status and the Choice of Supplementation DoseCédric Annweiler, MD, PhD1; Guillaume Duval, MD, MS1; Cyrille P. Launay, MD, PhD2 JAMA Intern Med. 2016;176(6):865. doi:10.1001/jamainternmed.2016.1612
  13. Less Is More June 2016 Estimating Vitamin D Status and the Choice of Supplementation Dose Cédric Annweiler, MD, PhD1; Guillaume Duval, MD, MS1; Cyrille P. Launay, MD, PhD2 Author Affiliations JAMA Intern Med. 2016;176(6):865. doi:10.1001/jamainternmed.2016.1612
  14. https://jamanetwork.com/journals/jama/fullarticle/2678622 Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling AdultsUS Preventive Services Task Force Recommendation Statement
  15. Garland CF, Kim JJ, Mohr SB, Gorham ED, Grant WB, Giovannucci EL, et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health (2014) 104(8):e43–50.10.2105/AJPH.2014.302034 [PMC free article] [PubMed] [Cross Ref]
  16. Sun YQ, Langhammer A, Skorpen F, Chen Y, Mai XM. Serum 25-hydroxyvitamin D level, chronic diseases and all-cause mortality in a population-based prospective cohort: the HUNT Study. Norway BMJ Open (2017) 7(6):e017256.10.1136/bmjopen-2017-017256 [PMC free article] [PubMed] [Cross Ref
  17. Gaksch M, Jorde R, Grimnes G, Joakimsen R, Schirmer H, Wilsgaard T, et al. Vitamin D and mortality: individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. PLoS One (2017).
  18. Quraishi SA, Bittner EA, Blum L, McCarthy CM, Bhan I, Camargo CA, Jr. Prospective study of vitamin D status at initiation of care in critically ill surgical patients and risk of 90-day mortality. Crit Care Med (2014) 42:1365–71.10.1097/CCM.0000000000000210 [PMC free article] [PubMed] [Cross Ref]
  19. Helde-Frankling M, Höijer J, Bergqvist J, Björkhem-Bergman L. Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-results from a matched case-control study. PLoS One (2017) 12(8):e0184208.10.1371/journal.pone.0184208 [PMC free article] [PubMed] [Cross Ref]
  20. Serum 25-Hydroxyvitamin D Values and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort Study Daniel V. Dudenkov, MDCorrespondence information about the author MD Daniel V. DudenkovEmail the author MD Daniel V. Dudenkov
  21. Tuohimaa P (March 2009). "Vitamin D and aging". The Journal of Steroid Biochemistry and Molecular Biology. 114 (1–2): 78–84. doi:1016/j.jsbmb.2008.12.020. PMID 19444937.
  22. Tuohimaa P, Keisala T, Minasyan A, Cachat J, Kalueff A (December 2009). "Vitamin D, nervous system and aging". Psychoneuroendocrinology. 34 Suppl 1: S278–86. doi:1016/j.psyneuen.2009.07.003. PMID19660871.
  23. Bi WG, Nuyt AM, Weiler H, Leduc L, Santamaria C, Wei SQ (May 2018). "Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis". JAMA Pediatrics. doi:1001/jamapediatrics.2018.0302. PMID29813153.
  24. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, Yaktine AL, Del Valle HB. 2011. [Medline].
  25. Evidence Does Not Support Vitamin D Supplements for All, Marlene Busko, November 29, 2016 Medscape Medical News